Animal studies have demonstrated that MPO inhibition significantly improves post-stroke neurological outcomes, with a reported 60% increase in Hsp70+/NeuN + neuronal survival (Kim et al., 2019). The gene discussed is RBFOX3; the disease is stroke disorder.